Provided by Tiger Trade Technology Pte. Ltd.

Pulmatrix

2.44
-0.0250-1.02%
Volume:5.04K
Turnover:12.45K
Market Cap:8.89M
PE:-1.43
High:2.53
Open:2.47
Low:2.44
Close:2.46
52wk High:10.40
52wk Low:2.15
Shares:3.65M
Float Shares:3.63M
Volume Ratio:0.84
T/O Rate:0.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7073
EPS(LYR):-2.6173
ROE:-79.47%
ROA:-47.09%
PB:1.88
PE(LYR):-0.93

Loading ...

BRIEF-Pulmatrix And Cullgen Continue To Pursue Merger

Reuters
·
Dec 18, 2025

Pulmatrix and Cullgen Waive No-Solicitation Clause to Explore Alternatives Amid Ongoing Merger Approval Process

Reuters
·
Dec 18, 2025

Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives

THOMSON REUTERS
·
Dec 18, 2025

Pulmatrix Inc - Co and Cullgen Waive "No Solicitation" Clause in Merger Agreement

THOMSON REUTERS
·
Dec 18, 2025

Pulmatrix Reports Q3 2025 Results and Strategic Shift

TIPRANKS
·
Oct 17, 2025

Pulmatrix reports Q3 EPS (24c) vs. (71c) last year

TIPRANKS
·
Oct 16, 2025

Biopharma Pulmatrix's Q3 revenue drops to $0 as trial ends, plans asset divestment

Reuters
·
Oct 16, 2025

Pulmatrix Q3 EPS $(0.24) Up From $(0.71) YoY

Benzinga
·
Oct 16, 2025

BRIEF-Pulmatrix Q3 EPS USD -0.24

Reuters
·
Oct 16, 2025

Pulmatrix Shareholders Approve Merger with Cullgen; Company Moves to Divest iSPERSE™ Technology and Migraine Assets

Reuters
·
Oct 16, 2025

Pulmatrix Q3 Operating Expenses USD 866 Thousand

THOMSON REUTERS
·
Oct 16, 2025

Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets

THOMSON REUTERS
·
Oct 16, 2025

Pulmatrix Q2 EPS $(0.42) Up From $(1.59) YoY

Benzinga
·
Aug 06, 2025

Pulmatrix Inc. Reports Q2 2025 Results: Revenues Drop to $0 from $1.6M, R&D Expenses Plummet by $2.8M

Reuters
·
Aug 06, 2025

Pulmatrix Inc. Advances Merger with Cullgen, Plans to Divest Inhalation Assets in 2025

Reuters
·
Aug 06, 2025

Pulmatrix Inc - Seeks Divestment of Isperse Patent Portfolio

THOMSON REUTERS
·
Aug 06, 2025

Pulmatrix Inc: to Also Potentially Divest Three Isperse Technology Related Clinical Programs

THOMSON REUTERS
·
Aug 06, 2025

Pulmatrix Q2 Operating Expenses USD 1.548 Million

THOMSON REUTERS
·
Aug 06, 2025

Pulmatrix Inc - Proposed Merger With Cullgen Anticipated to Close in 2025

THOMSON REUTERS
·
Aug 06, 2025

Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets

THOMSON REUTERS
·
Aug 06, 2025